Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 4 1Phase 1/2 1

Status

Completed 6

Sponsor Class

OTHER 3INDUSTRY 2NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 6

Conditions

Leukemia 11Prostatic Neoplasms 9Breast Neoplasms 9Leukemia, Myeloid, Acute 8Leukemia, Lymphocytic, Chronic, B-Cell 7Neuroblastoma 6Myelodysplastic Syndromes 6Multiple Myeloma 6Melanoma 6Lymphoma 6Glioblastoma 6Ovarian Neoplasms 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Glioma 4Osteosarcoma 3Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Kidney Neoplasms 3Fallopian Tube Neoplasms 3Breast Neoplasms, Male 3Neoplasms, Plasma Cell 2Neoplasms 2Medulloblastoma 2Hodgkin Disease 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Wilms Tumor 1Uveal Melanoma 1Urinary Bladder Neoplasms 1

Interventions

Ipilimumab 98pembrolizumab 83Nivolumab 82aldesleukin 51Cyclophosphamide 49Interleukin-2 38fludarabine phosphate 31Vemurafenib 31Dacarbazine 31dabrafenib 29trametinib 28Temozolomide 26fludarabine 25CTLA-4 Antigen 18Bevacizumab 18Radiosurgery 15Paclitaxel 15Carboplatin 14encorafenib 13binimetinib 13Introns 13talimogene laherparepvec 12Radiotherapy 12Interferon alpha-2 12spartalizumab 11cobimetinib 10atezolizumab 10sargramostim 9peginterferon alfa-2b 9montanide ISA 51 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Has results × Melanoma × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT00071981 2023-06-28

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Eastern Cooperative Oncology Group

Phase 2 Completed
175 enrolled 12 charts
Dermatologic

Melanoma

NCT02009397 2021-11-22

A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients

University of Louisville

Phase 1/2 Completed
27 enrolled 5 charts
Dermatologic

Melanoma

NCT02451488 2020-02-10

Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma

Mayo Clinic

Phase 4 Completed
8 enrolled 5 charts
Dermatologic

Melanoma

NCT00769704 2016-07-13

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

BioVex Limited

Phase 3 Completed
437 enrolled 19 charts
Dermatologic

Melanoma

NCT01368276 2015-12-18

An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma

BioVex Limited

Phase 3 Completed
31 enrolled 11 charts
Dermatologic

Melanoma

NCT00085423 2013-04-10

Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Dartmouth-Hitchcock Medical Center

Phase 2 Completed
20 enrolled 9 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡